-
Dingbin Liu/Chen Xu of JEV Nankai University found that the identification of fecal extracellular vesicles can be used as a novel biomarker for the non-invasive diagnosis and prognosis of colorectal
Time of Update: 2023-02-03
Colorectal cancer (CRC) is one of the most common malignancies and is usually detected late in the clinic.
In conclusion, the study shows that fEV can be used as a novel biomarker in the diagnosis and prognosis of colorectal cancer in a completely non-invasive manner, with high clinical sensitivity and sensitivity, providing new opportunities for large-scale colorectal cancer screening.
-
Neoadjuvant combined with radiotherapy double-fisted, some early breast cancer has been cured
Time of Update: 2022-11-15
Neoadjuvant therapy has saved some patients with early-stage breast cancer from surgeryThis is a multicenter, single-arm Phase II clinical trial conducted at 7 centers in the United States, requiring patients over the age of 40 years with at most one lymph node metastasis and no distant organ metastases, and are classified as triple-negative breast cancer or HER2-positive breast cancer.
-
Reconstructing the hope, Mövenpick Renaissance | Professor Shi Yuankai: the research and development status and challenges of domestic innovative drugs in the field of lymphoma and the listing
Time of Update: 2022-10-14
In recent years, with the continuous emergence of new drugs, lymphoma treatment plans have been continuously updated, and the overall survival of lymphoma patients has been continuously improved. Beca
-
【Cell】Structural images of T cell receptors, revealing the mechanism of action of T cell receptors
Time of Update: 2022-09-06
Researchers led by Lukas Suñac, Christoph Thomas and Robert Tampé of the Institute of Biochemistry at the University of Frankfurt, in collaboration with Simon Davis of the University of Oxford and Gerhard Hummer of the Max Planck Institute for Biophysics, have for the first time successfully visualized an antigen-binding protein in the Structure of the membrane-bound T-cell receptor complex together .
-
Fumbling forward: Inventory the upgrade path of ADC connectors
Time of Update: 2022-08-15
Although this ADC drug and the first-generation Mylotarg® both use cleavable linkers based on hydrazone bonds and disulfide bonds, However, it showed better plasma stability In 2017, the third-generation ADC drug Besponsa® was approved for marketing for the treatment of acute lymphoblastic leukemia.
-
2022 AACR Breaking With Tradition
Time of Update: 2022-06-18
Let's take a look at updated data from a phase II trial of adaptive abiraterone guided by mathematical modeling in metastatic castration-resistant prostate cancer (mCRPC) .
We applied this model to guide whether to start or end a treatment cycle with abiraterone in metastatic castration-resistant prostate cancer (mCRPC) .
-
New progress in targeted protein degradation
Time of Update: 2022-05-24
▲The mechanism of action of AUTOphagy-TArgeting Chimera (AUTOTAC) (Image source: Reference [1])Based on this concept, the researchers developed a variety of small-molecule compounds capable of activating p62 and tested their ability to degrade soluble proteins in vitro .
-
"NEJM" Three-year clinical trials in patients prove that gene therapy can reverse sickle cell disease
Time of Update: 2021-12-29
Four patients from New York Presbyterian Hospital/Columbia University Irvine Medical Center participated in this multicenter study, which is the first report of long-term results of sickle cell gene therapy .
-
NgAgo is completely useless of scientific research value
Time of Update: 2021-12-05
On November 8, 2021, Liu Yan and Guan Tuchen of Nantong University published a research paper entitled "Cadherin-12 Regulates Neurite Outgrowth Through the PKA/Rac1/Cdc42 Pathway in Cortical Neurons" in Frontiers in Cell and Developmental Biology.
-
Hepatology: Study on the mechanism of breviscapine in reducing non-alcoholic steatohepatitis
Time of Update: 2021-11-11
There are currently no approved specific drugs for the treatment of NASH.
RNA sequencing and multi-omics analysis further indicate that the key mechanism of breviscapine's anti-NASH effect is the inhibition of TAK1 phosphorylation and the subsequent MAPK signal cascade .
-
Moffitt researchers developed a model to predict the outcome of immunotherapy in patients with non-small cell lung cancer
Time of Update: 2021-09-04
Moffitt’s research team did not analyze common tissue-based biomarkers, such as protein expression patterns, but evaluated the potential of using pre-treatment CT scan features combined with clinical data to identify markers related to the outcome of immunotherapy .
-
Cancers: Water-soluble SIGLEC5 (sSIGLEC5): A new prognostic indicator for colorectal cancer
Time of Update: 2021-08-13
The study showed that water-soluble SIGLEC5 (sSIGLEC5) is a prognostic indicator for patients with colorectal cancer .
The study showed that water-soluble SIGLEC5 (sSIGLEC5) is a prognostic indicator for patients with colorectal cancer .
-
Nature Sub-Journal: Single Cell Fine Lipidomics Technology
Time of Update: 2021-08-11
Based on the identification and relative quantification of multiple types of lipid isomers in a single cell, the team achieved accurate identification of drug-resistant cells in the wild-type non-small cell lung cancer (HCC827) cell population, which is of great significance for the precise diagnosis and treatment of cancer .
-
Oncogene: This combination therapy can effectively treat metastatic melanoma
Time of Update: 2021-08-01
Spanish researchers have recently discovered that the combination therapy of chemotherapy and BRAF inhibitors is a very effective strategy for the treatment of metastatic melanoma .
In addition, because the combination therapy eliminates tumor cells instead of preventing their growth, it can also avoid prolonged treatment and the development of drug resistance .
-
Gold-absorbing target next one-CD137 to see how pharmaceutical giants set off an upsurge in research and development
Time of Update: 2021-07-30
Studies have shown that ADG106 shows good safety characteristics and preliminary anti-tumor activity: after a patient with non-Hodgkin’s lymphoma who had failed multi-line therapy received ADG106, the tumor burden of two of the six target lesions was reduced More than 50%; in addition, in many patients, potential biological activity and pharmacodynamic biomarker responses were also observed, including related changes in the expression of 4-1BB .
